Latest Boehringer Ingelheim Stories
CAMBRIDGE, Mass., Nov.
- RE-VERSE AD(TM) is being conducted in more than 35 countries with aim to enroll 250 patients RIDGEFIELD, Conn., Nov. 10, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
- Poster on research about investigational, specific antidote for PRADAXA also to be presented RIDGEFIELD, Conn., Nov. 10, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
Case Funding Company reaffirms increased funding amounts for Pradaxa Pre-Settlement and Settled Cases after $650MM settlement on approximately 4K filed cases over the blood thinner in state and federal
RIDGEFIELD, Conn., Nov. 3, 2014 /PRNewswire/ -- Boehringer Ingelheim today announced that the U.S.
Significant portion of alliance opportunity will remain unchanged; some countries will transition to exclusive promotion in 2015 INDIANAPOLIS and INGELHEIM, Germany, Oct.
LONDON and BOSTON, October 28, 2014 /PRNewswire/ -- Global top 20 pharma company streamlines R&D IT with cross-domain platform Boehringer Ingelheim,
Data for the co-administration of Spiriva® HandiHaler® (tiotropium bromide inhalation powder) + Striverdi® Respimat® (olodaterol) Inhalation Spray presented at CHEST 2014 RIDGEFIELD,
RIDGEFIELD, Conn. and INDIANAPOLIS, Oct. 21, 2014 /PRNewswire/ -- The U.S.
-- LUME-COLON 1 will evaluate the efficacy and safety of nintedanib in specific patients with metastatic colorectal cancer (mCRC) whose disease has progressed on previous treatment
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.